Register
Login:
Share:
Email Facebook Twitter


London South East Natural Resources Briefing webcast: #Emmerson #Alba #Condor Gold #Gold analysis
Angus Energy in talks to buy 'transformational' gas asset in North England


ShareCast News


C4X enters drug discovery AI deal with GTN

Thu, 29th Nov 2018 12:21


(Sharecast News) - Drug discovery company C4X Discovery Holdings has entered into a partnership with GTN, a new player in the field of drug discovery artificial intelligence, initially focussing on identifying potential small molecule hits against a high-value neurodegeneration target, it announced on Thursday.

The AIM-traded firm said artificial intelligence was expected to "revolutionise" the drug discovery industry, with GTN reportedly at the forefront of the field, using deep-learning techniques and quantum physics to simulate, filter and search for molecules that were hidden from traditional technologies.

However, it explained that over-simplistic representation of molecules was a "key challenge" for the application of artificial intelligence to problems of medicinal chemistry, resulting in suboptimal property prediction and thus suboptimal results.

In order to address that 'representation problem', C4X - using its conformational analysis platform 'Conformetrix' - would provide GTN with molecular descriptors for use in its in-silico discovery platform.

By combining both technologies, the collaboration was aiming to unlock new areas of chemical space and identify novel small molecules.

The board said the discovery partnership added another high value programme to C4X's portfolio, and represented continued progress against its strategy of accessing high impact technologies through productive partnerships.

"Strategic partnerships represent a critical component of our strategy and we are delighted to be collaborating with the team at GTN on this exciting project," said C4X Discovery's chief scientific officer Dr Craig Fox.

"Leveraging the clear synergies that exist between our Conformetrix platform and GTN's in-silico discovery technology, we aim to solve the representation problem and enable pioneering research into unexplored chemical space against a commercially attractive neurodegeneration target. We are looking forward to seeing the results of this project."

Noor Shaker, chief executive officer of GTN, added that the company was "excited" to be working with C4X Discovery.

"This partnership is a great milestone for GTN as we expand the capabilities of our proprietary quantum machine learning platform."

Shaker explained that GTN would deploy its platform to discover novel, high quality chemicals and accelerate the discovery process.

"GTN's unique approach to quantum representation of molecules and advance machine learning plays very nicely with C4X's molecular descriptors.

"It is a key component of GTN's strategy to form close collaborations with biotechs and pharmaceutical companies and we hope that this is the start of a growing relationship with C4X Discovery."





Back to ShareCast News


Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk




Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.